Drug intelligence / Profile preview

RNO-6

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical

Overview

RNO-6 is a novel nitric oxide (NO)-donating ripasudil derivative designed to leverage the synergistic therapeutic effects of NO and Rho-associated protein kinase (ROCK) inhibitors for glaucoma treatment. It demonstrates potent ROCK inhibitory and NO-releasing capabilities, leading to F-actin depolymerization and suppressed mitochondrial respiration in human trabecular meshwork (HTM) cells. Preclinical studies in chronic ocular hypertension glaucoma mice showed that topical administration of RNO-6 significantly lowered intraocular pressure (IOP) and provided protection for visual function and retinal ganglion cells (RGCs), outperforming an equimolar dose of ripasudil. RNO-6 is being investigated as a promising agent for glaucoma or ocular hypertension.

Targets

ROCK1 (Rho-associated coiled-coil containing protein kinase 1)NO2- (Nitrite)

Beyond the preview

Go deeper on RNO-6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNO-6.

Explore the full profile